Abstract
Nuclear factor (NF)-κB is regarded as one of the most important transcription factors and plays an essential role in the transcriptional activation of pro-inflammatory cytokines, cell proliferation and survival. NF-κB can be activated via two distinct NF-κB signal transduction pathways, the so-called canonical and non-canonical pathways, and has been demonstrated to play a key role in a wide range of inflammatory diseases and various types of cancer. Much effort has been put in strategies to inhibit NF-κB activation, for example by the development of pharmacological compounds that selectively inhibit NF-κB activity and therefore would be beneficial for immunotherapy of transplantation, autoimmune and allergic diseases, as well as an adjuvant approach in patients treated with chemotherapy for cancer. Gene therapy targeting NF-κB is a promising new strategy with the potential of long-term effects and has been explored in a wide variety of diseases, ranging from cancer to transplantation medicine and autoimmune diseases. In this review we discuss recent progress made in the development of NF-κB targeted gene therapy and the evolution towards clinical application.
Keywords: Gene therapy, NF-κB, signal transduction, siRNA, decoy oligodeoxynucleotides, adenovirus, adeno-associated virus, adoptive transfer
Current Gene Therapy
Title: Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Volume: 9 Issue: 3
Author(s): Sander W. Tas, Margriet J.B.M. Vervoordeldonk and Paul P. Tak
Affiliation:
Keywords: Gene therapy, NF-κB, signal transduction, siRNA, decoy oligodeoxynucleotides, adenovirus, adeno-associated virus, adoptive transfer
Abstract: Nuclear factor (NF)-κB is regarded as one of the most important transcription factors and plays an essential role in the transcriptional activation of pro-inflammatory cytokines, cell proliferation and survival. NF-κB can be activated via two distinct NF-κB signal transduction pathways, the so-called canonical and non-canonical pathways, and has been demonstrated to play a key role in a wide range of inflammatory diseases and various types of cancer. Much effort has been put in strategies to inhibit NF-κB activation, for example by the development of pharmacological compounds that selectively inhibit NF-κB activity and therefore would be beneficial for immunotherapy of transplantation, autoimmune and allergic diseases, as well as an adjuvant approach in patients treated with chemotherapy for cancer. Gene therapy targeting NF-κB is a promising new strategy with the potential of long-term effects and has been explored in a wide variety of diseases, ranging from cancer to transplantation medicine and autoimmune diseases. In this review we discuss recent progress made in the development of NF-κB targeted gene therapy and the evolution towards clinical application.
Export Options
About this article
Cite this article as:
Tas W. Sander, Vervoordeldonk J.B.M. Margriet and Tak P. Paul, Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer, Current Gene Therapy 2009; 9 (3) . https://dx.doi.org/10.2174/156652309788488569
DOI https://dx.doi.org/10.2174/156652309788488569 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Current Clinical Pharmacology Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway
Central Nervous System Agents in Medicinal Chemistry Targeting BLyS in Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery Potential Use of Drugs that Target Neural-Immune Pathways in the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Gene Expression Profiles in Human Autoimmune Disease
Current Pharmaceutical Design Vitamin D Receptor as a Drug Discovery Target
Mini-Reviews in Medicinal Chemistry Immune Aging and Autoimmune Diseases in Children
Current Immunology Reviews (Discontinued) To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease
Current Drug Targets Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design KIR Molecules: Recent Patents of Interest for the Diagnosis and Treatment of Several Autoimmune Diseases, Chronic Inflammation, and B-cell Malignancies
Recent Patents on DNA & Gene Sequences Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases
Reviews on Recent Clinical Trials Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Current Topics in Medicinal Chemistry Selenium and Autoimmune Diseases: A Review Article
Current Rheumatology Reviews Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Immune Monitoring to Predict the Development of Infections After Immunosuppression for Solid Organ Transplantation and Autoimmune Diseases
Current Drug Safety